Table 2.
Epidemiological and clinical data of patients with and without a strong first phase virological response.
| Patients with a greater than 2log10 48-h decrease in HCV titer (n=4) | Patients with a less than 2log10 48-h decrease in HCV titer (n=10) | |
|---|---|---|
| Decrease in HCV titer 0h-48h, median log10 (IQRa) | 2.59 (2.2– 2.9) | 1.15 (0.7–1.6) |
| Early virological response, n (%) | 4 (100%) | 9 (100%) c |
| Gender (male/female) | 3/1 | 6/4 |
| Age at start of treatment, median (IQR) years | 57.5 (54.3–60.8) | 53.0 (47.3–55.5) |
| Ethnicity (asian/african american/ caucasian/hispanic) | 1/1/2/0 | 1/3/5/1 |
| Body mass index, median (IQR) | 30.8 (22.9– 34.5) | 29 (25.6–35.9) |
| IL-28B rs12979860 SNPb (CC/CT/TT) | 3/0/0 | 4/4/2 |
| HCV genotype (1/4) | 4/0 | 7/1 |
| Serum HCV RNA titer at start of treatment, mean (±SEM) log10 IU/mL | 6.6 (±0.15) | 6.6 (±0.31) |
| ALT level at start of treatment, median (IQR) U/mL | 61 (36– 98) | 83 (62–179) |
a
IQR: interquartile range
b
SNP: single nucleotide polymorphism
c
one patient did not yet reach the week 12 time, thus was not evaluated for SVR.